Intrinsic value of NewAmsterdam Pharma Company N.V. (NAMS)
Live fair value data for NewAmsterdam Pharma Company N.V. (NAMS) is currently unavailable. Please check again shortly.
Current Price: $133.00
Valuation: Undervalued
Confidence: 6.5/10
Visual Bar
This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.
Is NewAmsterdam Pharma Company N.V. (NAMS) undervalued or overvalued?
Based on the current model output, NewAmsterdam Pharma Company N.V. appears to be undervalued with a upside of 26.00%.
Fair value vs market price — NewAmsterdam Pharma Company N.V. (NAMS)
Unlock premium access to view the live fair value comparison against current market price for NAMS.
Frequently Asked Questions - NAMS
How is NAMS intrinsic value estimated?
We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for NAMS.
Is NAMS undervalued or overvalued right now?
NAMS is currently shown as undervalued based on the difference between market price and intrinsic value.
How should I use the confidence score?
The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.
Related companies — intrinsic value
Peers for NAMS: open their intrinsic value pages.